Literature DB >> 10360365

Transition-state analogs as inhibitors of human and malarial hypoxanthine-guanine phosphoribosyltransferases.

C M Li1, P C Tyler, R H Furneaux, G Kicska, Y Xu, C Grubmeyer, M E Girvin, V L Schramm.   

Abstract

The proposed transition state for hypoxanthine-guanine phosphoribosyltransferases (HGPRTs) has been used to design and synthesize powerful inhibitors that contain features of the transition state. The iminoribitols (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate (immucillinHP) and (1S)-1-(9-deazaguanin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate (immucillinGP) are the most powerful inhibitors yet reported for both human and malarial HGPRTs. Equilibrium binding constants are >1,000-fold tighter than the binding of the nucleotide substrate. The NMR spectrum of malaria HGXPRT in the Michaelis complex reveals downfield hydrogen-bonded protons. The chemical shifts move farther downfield with bound inhibitor. The inhibitors are lead compounds for species-specific antibiotics against parasitic protozoa. The high-resolution crystal structure of human HGPRT with immucillinGP is reported in the companion paper.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360365     DOI: 10.1038/9367

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  17 in total

1.  Combinatorial minimization and secondary structure determination of a nucleotide synthase ribozyme.

Authors:  Kelly E Chapple; David P Bartel; Peter J Unrau
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

2.  Acyclic immucillin phosphonates: second-generation inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.

Authors:  Keith Z Hazleton; Meng-Chiao Ho; Maria B Cassera; Keith Clinch; Douglas R Crump; Irving Rosario; Emilio F Merino; Steve C Almo; Peter C Tyler; Vern L Schramm
Journal:  Chem Biol       Date:  2012-06-22

3.  Pyrophosphate activation in hypoxanthine--guanine phosphoribosyltransferase with transition state analogue.

Authors:  Hua Deng; Robert Callender; Vern L Schramm; Charles Grubmeyer
Journal:  Biochemistry       Date:  2010-03-30       Impact factor: 3.162

Review 4.  Purine salvage pathways in the intraerythrocytic malaria parasite Plasmodium falciparum.

Authors:  Megan J Downie; Kiaran Kirk; Choukri Ben Mamoun
Journal:  Eukaryot Cell       Date:  2008-06-20

5.  Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontier.

Authors:  Kyu Y Rhee; Luiz Pedro Sorio de Carvalho; Ruslana Bryk; Sabine Ehrt; Joeli Marrero; Sae Woong Park; Dirk Schnappinger; Aditya Venugopal; Carl Nathan
Journal:  Trends Microbiol       Date:  2011-05-10       Impact factor: 17.079

Review 6.  Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Authors:  María Belén Cassera; Yong Zhang; Keith Z Hazleton; Vern L Schramm
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

7.  Synthesis of bis-Phosphate Iminoaltritol Enantiomers and Structural Characterization with Adenine Phosphoribosyltransferase.

Authors:  Lawrence D Harris; Rajesh K Harijan; Rodrigo G Ducati; Gary B Evans; Brett M Hirsch; Vern L Schramm
Journal:  ACS Chem Biol       Date:  2017-12-14       Impact factor: 5.100

8.  Kinetic Isotope Effects and Transition State Structure for Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase from Plasmodium falciparum.

Authors:  Rodrigo G Ducati; Ross S Firestone; Vern L Schramm
Journal:  Biochemistry       Date:  2017-11-21       Impact factor: 3.162

Review 9.  Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria.

Authors:  Rodrigo G Ducati; Hilda A Namanja-Magliano; Vern L Schramm
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

10.  Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis.

Authors:  Carola Huthmacher; Andreas Hoppe; Sascha Bulik; Hermann-Georg Holzhütter
Journal:  BMC Syst Biol       Date:  2010-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.